Accelerated evolution of resistance in multidrug environments

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 37, 2008, Pages 13977-13981

  Hegreness, Matthew ^a,b   Shoresh, Noam ^a   Damian, Doris ^d   Hartl, Daniel ^b   Kishony, Roy ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

Adaptation; Antagonism; Antibiotic resistance; Antibiotics; Synergy

Indexed keywords

AMIKACIN; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; AUTOMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ANTAGONISM; DRUG POTENTIATION; ESCHERICHIA COLI; EVOLUTIONARY ADAPTATION; GEOMETRY; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; PRIORITY JOURNAL;

ADAPTATION, BIOLOGICAL; DRUG RESISTANCE, MULTIPLE; EVOLUTION;

ESCHERICHIA COLI;

EID: 52949141463     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805965105     Document Type: Article

References (30)

1. Daniels M, Hill AB (1952) Chemotherapy of pulmonary tuberculosis in young adults - An analysis of the combined results of 3 Medical Research Council trials. Brit Med J 1:1162-1168.
2. Klastersky J, Cappel R, Daneau D (1972) Clinical significance of in-vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother 2:470-475.
3. Davies J, Wright GD (1997) Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 5:234-240.
4. Smith RD, Coast J (2002) Antimicrobial resistance:Aglobal response. Bull World Health Organ 80:126-133.
5. Walsh, C (2003) Antibiotics: Actions, Origins, Resistance (American Society for Microbiology Press, Washington, DC).
6. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: Causes, challenges and responses. Nature Med 10:S122-S129.
7. Norrby SR, Nord CE, Finch R (2005) Lack of development of new antimicrobial drugs: A potential serious threat to public health. Lancet Infect Dis 5:115-119.
8. Berenbaum MC (1989) What is synergy. Pharmacol Rev 41:93-141.
9. Greco WR, Bravo G, Parsons JC (1995) The search for synergy - A critical-review from a response-surface perspective. Pharmacol Rev 47:331-385.
10. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149-158.
11. Sweany HC, Dunbar FP, Wood E (1955) The problem of bacterial resistance in antimicrobial therapy of tuberculosis. Dis Chest 28:260-274.
12. Eggimann P, Revelly JP (2006) Should antibiotic combinations be used to treat ventilator-associated pneumonia? Semin Respir Crit Care Med 27:68-81.
13. Pillai SK, Moellering RC, Eliopoulos GM (2005) in Antibiotics in Laboratory Medicine, ed Lorian V (Lippincott Williams & Wilkins, Philadelphia), pp 365-440.
14. Daschner FD (1976) Combination of bacteriostatic and bactericidal drugs - Lack of significant invitro antagonism between penicillin, cephalothin, and rolitetracycline. Antimicrob Agents Chemother 10:802-808.
15. Klein M, Schorr SE (1953) The role of bacterial resistance in antibiotic synergism and antagonism. J Bacteriol 65:454-465.
16. Lipsitch M, Levin BR (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41:363-373.
17. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446:668-671.
18. Jawetz E (1954) Infectious diseases - Problems of antimicrobial therapy. Annu Rev Med 5:1-26.
19. Gunnison JB, Shevky MC, Bruff JA, Coleman VR, Jawetz E (1953) Studies on antibiotic synergism and antagonism - The effect invitro of combinations of antibiotics on bacteria of varying resistance to single antibiotics. J Bacteriol 66:150-158.
20. Rodriguez-Martinez JM, et al. (2007) Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob Agents Chemother 51:2236-2239.
21. Yeh P, Tschumi AI, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38:489-494.
22. Chopra I, Roberts M (2001) Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232-260.
23. Elena SF, Lenski RE (2003) Evolution experiments with microorganisms: The dynamics and genetic bases of adaptation. Nat Rev Genet 4:457-469.
24. Hegreness M, Shoresh N, Hartl D, Kishony R (2006) An equivalence principle for the incorporation of favorable mutations in asexual populations. Science 311:1615-1617.
25. DeLuna A, et al. (2008) Exposing the fitness contribution of duplicated genes. Nat Genet 40:676-681.
26. Berenbaum MC, Yu VL, Felegie TP (1983) Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother 12:555-563.
27. Chao L (1978) Unusual interaction between target of nalidixic-acid and novobiocin. Nature 271:385-386.
28. Szybalski W (1954) Genetic studies on microbial cross resistance to toxic agents. 4. Cross resistance of bacillus-megaterium to 44 antimicrobial drugs. Appl Microbiol 2:57-63.
29. Weinreich DM, Delaney NF, DePristo MA, Hartl DL (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114.
30. Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52:11-17.